Author:
Eisen T,Loembé A-B,Shparyk Y,MacLeod N,Jones R J,Mazurkiewicz M,Temple G,Dressler H,Bondarenko I
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Boehringer Ingelheim (2014a) Ofev® (nintedanib) prescribing information [Online]. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2014/205832s000lbl.pdf (accessed on April 2015).
2. Boehringer Ingelheim (2014b) Vargatef® (nintedanib) summary of product characteristics [Online]. Available at: www.ema.europa.eu (accessed on April 2015).
3. Bukowski RM (2012) Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma. Front Oncol 2: 13.
4. Cancer Therapy Evaluation Program (2006) Common Terminology Criteria for Adverse Events Version 3.0 [Online] Available http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf accessed September 2015.
5. Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299–309.
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献